Biodexa Pharmaceuticals (BDRX) Net Income towards Common Stockholders (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$5.1 million in Q2 2025.

• For the quarter ending Q2 2025, Net Income towards Common Stockholders changed N/A year-over-year to -$5.1 million; the trailing twelve-month figure through Dec 2025 stood at -$8.3 million (up 51.14% YoY), and the FY2025 full-year result was -$8.7 million, down 171.06% from the prior year.
• Net Income towards Common Stockholders retreated to -$5.1 million in Q2 2025, from -$3.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$3.2 million in Q4 2024 to a low of -$9.3 million in Q4 2023.
• A 5-year average of -$4.8 million and a median of -$4.3 million in 2021 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders soared 81.45% in 2021 and slumped 158.92% in 2023, its largest moves.
• Tracing BDRX's Net Income towards Common Stockholders over 5 years: stood at -$4.2 million in 2021, then rose by 15.61% to -$3.6 million in 2022, then tumbled by 158.92% to -$9.3 million in 2023, then soared by 65.45% to -$3.2 million in 2024, then tumbled by 58.3% to -$5.1 million in 2025.
• Business Quant data shows BDRX's Net Income towards Common Stockholders at -$5.1 million in Q2 2025, -$3.2 million in Q4 2024, and -$9.3 million in Q4 2023.